Who
James O. Armitage
Director
Company insider
Files Form 4 as: Director, Cardiff Oncology; Director, Tesaro; Director, Mgi Pharma.
In numbers
- Trades disclosed
- 36
- Buys
- 5
- Sells
- 1
- Bought
- $144K
- Sold
- $1.2M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 21 Jul 2006
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,565 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,565 at $0.00 | filing |
| 26 Jun 2025filed 27 Jun 2025 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,565 at $0.00 | filing |
| 27 Jun 2024filed 1 Jul 2024 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,700 at $0.00 | filing |
| 15 Jun 2023filed 20 Jun 2023 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,700 at $0.00 | filing |
| 16 Sep 2022filed 11 Oct 2022 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $20K13,000 at $1.56 | filing |
| 9 Mar 2022filed 10 Mar 2022 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,800 at $0.00 | filing |
| 10 Jun 2021filed 14 Jun 2021 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 19 Mar 2021filed 27 May 2021 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $43K4,000 at $10.82 | filing |
| 17 Jun 2020filed 19 Jun 2020 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,858 at $0.00 | filing |
| 14 May 2020filed 18 May 2020 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $15K10,490 at $1.43 | filing |
| 16 Apr 2020filed 1 May 2020 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,916 at $0.00 | filing |
| 22 Jan 2019filed 22 Jan 2019 | Tesarooption or derivative | SEC FORM 4 Code D | —4,052 | filing |
| 22 Jan 2019filed 22 Jan 2019 | Tesarooption or derivative | SEC FORM 4 Code D | —25,000 | filing |
| 22 Jan 2019filed 22 Jan 2019 | Tesarooption or derivative | SEC FORM 4 Code D | —10,000 | filing |
| 22 Jan 2019filed 22 Jan 2019 | Tesarooption or derivative | SEC FORM 4 Code D | —12,000 | filing |
| 22 Jan 2019filed 22 Jan 2019 | Tesarooption or derivative | SEC FORM 4 Code D | —12,000 | filing |
| 22 Jan 2019filed 22 Jan 2019 | Tesarooption or derivative | SEC FORM 4 Code D | —7,209 | filing |
| 22 Jan 2019filed 22 Jan 2019 | Tesaro | SEC FORM 4 Code U | $113K1,500 at $75.00 | filing |
| 1 Jun 2018filed 5 Jun 2018 | Tesarooption or derivative | SEC FORM 4 Code A | —7,209 at $0.00 | filing |
News
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic LeukemiaCRDF · manilatimes.net · 21 Oct 2026Analyzing Cardiff Oncology (NASDAQ:CRDF) and Xencor (NASDAQ:XNCR)CRDF · themarketsdaily.com · 21 Oct 2026
0 headlines in the last 90 days name James O. Armitage; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.